Drug-Resistant Epilepsy & Dystonia
Drug Resistant Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures arising from abnormal electrical activity in the brain. Although antiseizure medications are the primary treatment, approximately 30% of patients continue to experience disabling seizures despite adequate trials of at least two appropriate medications. This subgroup is defined as drug-resistant epilepsy (DRE) and often faces substantial impairments in quality of life, including cognitive difficulties, psychological distress, social limitations, and increased risk of injury (Zangiabadi et al., 2019; Vetkas et al., 2022). In children, DRE is particularly impactful, interrupting development, education, and psychosocial functioning, and frequently requiring advanced neuromodulation or surgical interventions (Starnes et al., 2019; Uchitel et al., 2025).
Dystonia is a movement disorder characterized by involuntary, sustained, or intermittent muscle contractions resulting in abnormal postures or repetitive movements. It may be primary/genetic (e.g., DYT1) or secondary due to brain injury, metabolic disorders, or neurodegenerative conditions. Many patients show limited or incomplete response to oral medications and botulinum toxin, particularly when dystonia is generalized or segmental (Rodrigues et al., 2019). Severe dystonia can significantly restrict mobility, daily activities, and social participation, and may be associated with pain, exhaustion, and musculoskeletal complications (Fan et al., 2021; Hock et al., 2022).
Both DRE and dystonia share a common challenge: they can remain refractory to conventional medical therapy and often require advanced treatments targeting disrupted neural circuits. Deep brain stimulation (DBS) has emerged as a key therapeutic option for these conditions, offering the possibility of meaningful improvement when standard treatments fail. As understanding of brain networks grows, DBS continues to expand as a safe, programmable, and effective therapy across both epilepsy and movement disorders.
Understanding Drug-Resistant Epilepsy
Why DBS for DRE and Dystonia?
Deep brain stimulation (DBS) has become an essential therapeutic option for patients with neurological conditions that do not respond adequately to standard treatments. In drug-resistant epilepsy (DRE), ongoing seizures persist despite trials of at least two appropriate antiseizure medications. For many of these patients, resective surgery may not be possible due to multifocal seizure onset, involvement of eloquent cortex, or generalized seizure networks. DBS offers a reversible, programmable, and network-level intervention, making it suitable for patients who are not candidates for curative surgery. Clinical evidence consistently demonstrates that DBS—particularly targeting the anterior nucleus of the thalamus (ANT) and centromedian nucleus (CMN)—reduces seizure frequency and improves long-term responder rates in patients with refractory focal and generalized epilepsies (Vetkas et al., 2022; Zangiabadi et al., 2019; Dhaliwal et al., 2025). Pediatric data also show significant benefit, with many children achieving meaningful seizure reduction when other therapies fail (Starnes et al., 2019; Uchitel et al., 2025).
In dystonia, medication response is often limited, especially in generalized or segmental forms. Oral agents frequently provide only partial relief, while botulinum toxin injections may be insufficient for widespread muscle groups. DBS—most commonly targeting the globus pallidus internus (GPi)—has demonstrated robust improvements in motor severity, daily functioning, and quality of life, particularly in primary dystonias such as DYT1 (Rodrigues et al., 2019; Fan et al., 2021). Long-term randomized and observational studies report sustained benefit for up to 10–15 years, with high patient satisfaction and durable symptom control (Hock et al., 2022).
Across both conditions, the advantages of DBS include adjustability, reversibility, the ability to tailor stimulation to patient needs, and the potential to modulate dysfunctional circuits without removing or destroying brain tissue. For individuals living with persistent seizures or disabling dystonia despite optimal medical therapy, DBS offers one of the most effective and flexible advanced neuromodulation treatments available today.
DBS Procedure & Targets
Deep brain stimulation (DBS) for drug-resistant epilepsy and dystonia involves implanting thin electrodes into specific deep brain structures that regulate abnormal electrical or motor network activity. The procedure is performed using stereotactic neurosurgical techniques, guided by high-resolution MRI and CT imaging. In many centers, microelectrode recordings or test stimulation are used intraoperatively to refine placement and confirm functional accuracy (Zangiabadi et al., 2019). Once positioned, the electrodes are connected to an implantable pulse generator (IPG) placed under the skin of the chest. Programming begins a few weeks later and is adjusted over multiple sessions to optimize symptom control while minimizing side effects (Starnes et al., 2019).
Targets in Drug-Resistant Epilepsy
Several brain regions have been explored for epilepsy DBS, but the most established target is the anterior nucleus of the thalamus (ANT). ANT plays a key role in seizure propagation through the Papez circuit, and stimulation here consistently reduces seizure frequency in focal and multifocal epilepsies (Vetkas et al., 2022; Dhaliwal et al., 2025).
The centromedian nucleus (CMN) is another important target, particularly effective for generalized epilepsies and syndromes such as Lennox–Gastaut, given its role in widespread thalamocortical activation (Zangiabadi et al., 2019; Yassin et al., 2024).
In select patients, especially those with mesial temporal lobe epilepsy, hippocampal DBS has shown benefit by directly modulating seizure-generating networks, although this remains less widely adopted (Touma et al., 2022).
Pediatric experiences mirror adult findings, with ANT and CMN DBS demonstrating meaningful seizure reduction when other surgical options are not possible (Uchitel et al., 2025; Starnes et al., 2019).
Targets in Dystonia
In dystonia, the primary and most effective DBS target is the globus pallidus internus (GPi). GPi stimulation improves abnormal muscle contractions, reduces involuntary movements, and provides substantial functional gains, particularly in primary dystonia (Rodrigues et al., 2019; Fan et al., 2021).
The subthalamic nucleus (STN) is an alternative target with faster onset of benefit and strong long-term results in select cases. Head-to-head long-term comparisons show durable improvements for both GPi and STN, with some differences based on dystonia subtype and symptom profile (Hock et al., 2022).
Clinical Outcomes & Long-Term Efficacy
Deep brain stimulation (DBS) has demonstrated significant and durable clinical benefits for both drug-resistant epilepsy (DRE) and dystonia, with a growing body of evidence from randomized trials, long-term cohort studies, and pediatric series.
Clinical Outcomes in Drug-Resistant Epilepsy:
Across multiple systematic reviews and meta-analyses, ANT-DBS consistently shows meaningful seizure reduction in adults with focal and multifocal DRE. Meta-analytic data reveal that more than half of patients achieve a ≥50% reduction in seizure frequency, a key marker of treatment response, with responder rates increasing over time (Vetkas et al., 2022; Dhaliwal et al., 2025). Long-term follow-up studies show progressive improvement, with many individuals experiencing greater benefit after 2–5 years of continuous stimulation, reflecting a network-level neuromodulatory effect rather than an immediate suppressive action (Zangiabadi et al., 2019).
CMN-DBS has shown particular effectiveness for generalized epilepsies and syndromes such as Lennox–Gastaut syndrome (LGS). Several studies document robust reductions in tonic, atonic, and generalized tonic–clonic seizures, with responder rates comparable to or exceeding ANT stimulation in these populations (Yassin et al., 2024). Hippocampal DBS offers an additional option for mesial temporal lobe epilepsy, demonstrating consistent but modest seizure reduction in patients not eligible for resective surgery (Touma et al., 2022).
Pediatric outcomes closely mirror adult findings. In children with severe DRE including developmental epileptic encephalopathies DBS frequently results in clinically significant improvements. Pediatric series report ≥50% seizure reduction in a substantial proportion of patients, with additional gains in attention, behavior, and overall function (Starnes et al., 2019; Uchitel et al., 2025).
Clinical Outcomes in Dystonia:
DBS is highly effective in dystonia, particularly when targeting the globus pallidus internus (GPi). Randomized controlled trials and Cochrane-level evidence demonstrate marked improvement in motor scores, functional independence, and quality of life (Rodrigues et al., 2019). In primary dystonias such as DYT1, outcomes are especially strong, with many patients achieving sustained reductions in abnormal posturing and disability (Fan et al., 2021). Improvements typically develop gradually over weeks to months.
The subthalamic nucleus (STN) is also an effective target, offering similar long-term outcomes with potentially faster onset of improvement. Comparative long-term data, including follow-up up to 15 years, show durable benefits for both GPi and STN stimulation, with excellent safety and stable device performance (Hock et al., 2022).
Long-Term Efficacy Across Conditions:
Across both DRE and dystonia, long-term data consistently demonstrate that DBS benefits are sustained, progressive, and functionally meaningful. Many patients continue to show improvement beyond the first year, with maintained responder rates, reduced disability, and enhanced daily function. DBS does not halt the underlying disease, but it significantly improves symptom control, independence, and quality of life in patients with otherwise refractory neurological conditions.
Side Effects & Safety Profile
Deep brain stimulation (DBS) is generally considered a safe and well-tolerated therapy for both drug-resistant epilepsy (DRE) and dystonia. Safety data from randomized trials, long-term cohort studies, and pediatric series indicate that serious complications are uncommon and that most side effects are mild, transient, or manageable with programming adjustments.
Surgical and Device-Related Risks
Stereotactic electrode implantation carries a low risk of hemorrhage, infection, and hardware malfunction. Reported rates of symptomatic intracranial hemorrhage and postoperative infection remain below a few percent in large clinical series (Zangiabadi et al., 2019). Hardware-related complications such as lead fracture, migration, or pulse generator issues are infrequent and usually correctable through revision surgery (Vetkas et al., 2022).
Stimulation-Related Side Effects in Epilepsy
In DRE, stimulation of the anterior nucleus (ANT) or centromedian nucleus (CMN) can occasionally produce transient paresthesias, mild cognitive changes, mood fluctuations, or sleep disturbances. However, these effects are typically dose-dependent and resolve with programming optimization (Dhaliwal et al., 2025; Touma et al., 2022). Importantly, long-term cognitive decline has not been associated with ANT or CMN DBS, including in pediatric patients, where developmental trajectories generally stabilize or improve after seizure reduction (Starnes et al., 2019; Uchitel et al., 2025).
Stimulation-Related Side Effects in Dystonia
For dystonia, GPi DBS may cause transient dysarthria, bradykinesia, or gait imbalance, particularly at higher stimulation amplitudes. Likewise, STN stimulation may produce mild speech or balance disturbances early in therapy, but symptoms typically improve with careful parameter adjustments (Fan et al., 2021). Long-term randomized and observational data demonstrate an excellent safety record, with stable neuropsychological profiles and low rates of serious adverse events over 10–15 years of follow-up (Hock et al., 2022).
Overall Safety Profile
Across all targets, the majority of adverse effects are reversible, stimulation-related, and manageable through parameter modification. DBS avoids the neurocognitive risks associated with destructive procedures and provides a long-term therapeutic option with strong functional outcomes and a favorable safety profile.
DBS vs Other Treatment Options
Management of drug-resistant epilepsy (DRE) and dystonia involves a spectrum of therapeutic options, each with distinct mechanisms, benefits, and limitations. DBS occupies a unique position within this landscape as a reversible, adjustable, circuit-level therapy that does not require removal or destruction of brain tissue.
In both DRE and dystonia, failure of standard medication is the primary indication for DBS. Approximately one-third of epilepsy patients remain refractory despite trials of multiple antiseizure medications, leaving them vulnerable to uncontrolled seizures and impaired quality of life (Zangiabadi et al., 2019; Vetkas et al., 2022). Similarly, oral agents for dystonia—such as anticholinergics, GABAergic medications, and benzodiazepines—often provide only modest relief and are limited by systemic side effects (Fan et al., 2021). DBS provides superior and sustained symptom reduction once pharmacologic options are exhausted.
DBS vs Resective or Ablative Epilepsy Surgery
Traditional resective epilepsy surgery can be curative but is only appropriate for patients with well-localized, unilateral seizure foci. Many individuals with multifocal epilepsy, bilateral involvement, or eloquent cortex-onset seizures are not surgical candidates. For these patients, DBS offers a viable alternative that avoids irreversible tissue removal and provides broad network modulation (Touma et al., 2022; Dhaliwal et al., 2025).
DBS vs VNS and RNS
Vagus nerve stimulation (VNS) is less invasive but often yields smaller reductions in seizure frequency compared with thalamic DBS, especially in generalized epilepsies or complex seizure networks (Starnes et al., 2019). Responsive neurostimulation (RNS) requires clearly identifiable seizure onset zones and does not suit patients with multifocal or generalized epilepsies. DBS, particularly targeting ANT or CMN, remains the most flexible option for these populations (Yassin et al., 2024).
DBS vs Dystonia-Specific Alternatives
For dystonia, botulinum toxin is effective for focal symptoms but inadequate for generalized presentations. Surgical alternatives such as pallidotomy offer benefit but are irreversible and carry risks of permanent deficits. DBS, especially GPi targeting, provides long-term, adjustable symptom control with an excellent safety profile (Rodrigues et al., 2019; Hock et al., 2022).
Overall Comparison
Across both conditions, DBS offers a balance of efficacy, reversibility, and customization, positioning it as one of the most effective advanced therapies when conventional treatments fail.
Advances in Epilepsy & Dystonia Neuromodulation
Rapid progress in neuromodulation technologies has significantly expanded the therapeutic potential of DBS for both drug-resistant epilepsy (DRE) and dystonia. Modern systems increasingly emphasize precision, network-level modulation, and personalization, aiming to maximize efficacy while reducing side effects.
Network-Guided Targeting and Imaging Innovations
Advances in neuroimaging particularly diffusion tensor tractography and connectome-based analysis have enhanced understanding of the thalamocortical and basal ganglia networks. These tools help refine electrode placement in epilepsy targets such as the anterior nucleus (ANT), centromedian nucleus (CMN), and hippocampus, ensuring that stimulation engages clinically relevant circuits (Vetkas et al., 2022; Touma et al., 2022). In dystonia, improved mapping of pallidal and subthalamic networks supports more accurate targeting and prediction of treatment response (Fan et al., 2021).
Directional Leads and Optimized Programming
Next-generation DBS systems use directional (segmented) electrodes, enabling current steering toward therapeutic pathways while avoiding structures that cause side effects. This has improved tolerability and expanded the therapeutic window in both epilepsy and dystonia (Zangiabadi et al., 2019). Enhanced programming algorithms, including automated parameter optimization, further refine outcomes and reduce clinician burden.
Adaptive and Closed-Loop DBS
A major innovation is the development of adaptive (closed loop) DBS, in which stimulation adjusts dynamically based on real-time neural activity. Although still emerging, early findings suggest that adaptive systems may provide more efficient seizure control in epilepsy and more stable motor improvement in dystonia by reducing unnecessary stimulation and lowering power consumption (Yassin et al., 2024; Uchitel et al., 2025).
Pediatric Applications and Long-Term Expansion
In children, technological refinements have facilitated safer and more effective implantation, expanding DBS candidacy for severe epileptic encephalopathies and complex dystonia presentations (Starnes et al., 2019; Uchitel et al., 2025). Long-term data including 10–15 year outcomes in dystonia demonstrate the durability and stability of modern DBS systems (Hock et al., 2022).
Future Directions
As understanding of brain networks deepens and device technology evolves, DBS is moving toward highly personalized neuromodulation strategies that integrate biomarkers, adaptive algorithms, and connectome-based targeting. These advances promise more precise control of seizures and abnormal movements with fewer stimulation-related side effects.
References
Dhaliwal, J., et al. (2025). Deep brain stimulation for epilepsy: A systematic review and meta-analysis of randomized controlled trials. Seizure, 120, 1–15.
Fan, H., et al. (2021). Deep brain stimulation for dystonia: A review of patient selection, targets, and outcomes. Frontiers in Human Neuroscience, 15, 757579.
Hock, A. N., et al. (2022). Deep brain stimulation for dystonia: Long-term outcomes of GPi and STN stimulation up to 15 years. Parkinsonism and Related Disorders, 97, 45–53.
Rodrigues, F. B., et al. (2019). Deep brain stimulation for dystonia. Cochrane Database of Systematic Reviews, 1, CD012405.
Starnes, K., et al. (2019). Neurostimulation for pediatric epilepsy: A comprehensive review of VNS, RNS, and DBS. Brain Sciences, 9(11), 283.
Touma, L., et al. (2022). Neurostimulation in people with drug-resistant epilepsy: Systematic review and meta-analysis from the ILAE Surgical Therapies Commission. Epilepsia, 63(7), 1699–1723.
Uchitel, J., et al. (2025). Intracranial neuromodulation for pediatric drug-resistant epilepsy: Institutional review and clinical outcomes. Frontiers in Surgery, 12, 1569360.
Vetkas, A., et al. (2022). Deep brain stimulation targets in epilepsy: Systematic review and meta-analysis. Epilepsia, 63(1), 123–140.
Yassin, A., et al. (2024). Deep brain stimulation in drug-resistant epilepsy: Target effectiveness and predictors of response. Seizure, 110, 1–11.